Algorae Pharmaceuticals LVCLF Stock
Algorae Pharmaceuticals Price Chart
Algorae Pharmaceuticals LVCLF Financial and Trading Overview
| Algorae Pharmaceuticals stock price | 0.0072 USD |
| Previous Close | 0.00716 USD |
| Open | 0.0035 USD |
| Bid | 0.0048 USD x 23700000 |
| Ask | 0.01 USD x 2000000 |
| Day's Range | 0.0035 - 0.0035 USD |
| 52 Week Range | 0.0035 - 0.00955 USD |
| Volume | 40K USD |
| Avg. Volume | 789 USD |
| Market Cap | 14.52M USD |
| Beta (5Y Monthly) | -0.117 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
LVCLF Valuation Measures
| Enterprise Value | 10.58M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.093258 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Algorae Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.117 |
| 52-Week Change | 46.12% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 0.00955 USD |
| 52 Week Low | 0.0035 USD |
| 50-Day Moving Average | 0.0090466 USD |
| 200-Day Moving Average | 0.00859465 USD |
LVCLF Share Statistics
| Avg. Volume (3 month) | 789 USD |
| Avg. Daily Volume (10-Days) | 5.05K USD |
| Shares Outstanding | 2.03B |
| Float | 1.47B |
| Short Ratio | N/A |
| % Held by Insiders | 35.29% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -41.92% |
| Return on Equity (ttm) | -83.53% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -2710723 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.94M USD |
| Total Cash Per Share (mrq) | 0.002 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 25.113 |
| Book Value Per Share (mrq) | 0.00140578 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2603932 USD |
| Levered Free Cash Flow (ttm) | -1374572 USD |
Profile of Algorae Pharmaceuticals
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | Rialto South Tower |
| ZIP | 3000 |
| Phone | N/A |
| Website | https://algoraepharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Q&A For Algorae Pharmaceuticals Stock
What is a current LVCLF stock price?
Algorae Pharmaceuticals LVCLF stock price today per share is 0.0072 USD.
How to purchase Algorae Pharmaceuticals stock?
You can buy LVCLF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Algorae Pharmaceuticals?
The stock symbol or ticker of Algorae Pharmaceuticals is LVCLF.
Which industry does the Algorae Pharmaceuticals company belong to?
The Algorae Pharmaceuticals industry is Biotechnology.
How many shares does Algorae Pharmaceuticals have in circulation?
The max supply of Algorae Pharmaceuticals shares is 2.02B.
What is Algorae Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Algorae Pharmaceuticals PE Ratio is now.
What was Algorae Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Algorae Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Algorae Pharmaceuticals company belong to?
The Algorae Pharmaceuticals sector is Healthcare.
